Clinical Trials

21 enrolled 12 charts

CNS

Brain Neoplasms, Glioblastoma

NCT03307759 2025-09-15

SABRseq

13 enrolled 14 charts

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

52 enrolled 13 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

DermatologicGenitourinaryHead & NeckThoracic

146 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

260 enrolled 52 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

GastrointestinalGenitourinaryThoracic

185 enrolled 28 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04904185 2025-07-25

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

8 enrolled 8 charts

Dermatologic

Melanoma

NCT04153565 2025-07-17

MK-3475-A17

Other solid neoplasmThoracic

19 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

15 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT03286114 2025-05-11

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

LymphoidMyeloidOther hematologic neoplasm

16 enrolled 13 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04317066 2025-04-06

KEYNOTE-A33

7 enrolled 13 charts

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT05267470 2025-03-25

FORTITUDE-201

74 enrolled 22 charts

Phase 1 Active not recruiting

Squamous-Cell Non-Small-Cell Lung Cancer

NCT02852655 2025-03-13

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

60 enrolled 19 charts

CNS

Brain Neoplasms

NCT05446129 2025-03-13

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

2 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms

NCT03665597 2025-02-10

KEYNOTE-555

138 enrolled 34 charts 2 FDA

Dermatologic

Melanoma

NCT03948763 2025-01-28

V941-001

70 enrolled 18 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03032107 2025-01-27

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

20 enrolled 14 charts

Breast

Breast Neoplasms

NCT04074759 2025-01-23

FPT155-001

80 enrolled 49 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02630823 2025-01-03

MK-3475 Immunotherapy in Endometrial Carcinoma

10 enrolled 9 charts

Gynecologic

Endometrial Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

829 enrolled 100 charts

Tumor-Agnostic

Neoplasms

NCT03092453 2024-12-24

Dendritic Cell Vaccination in Patients With Advanced Melanoma

5 enrolled 10 charts

Dermatologic

Melanoma

NCT02972034 2024-11-21

MK-8353-013

111 enrolled 30 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03374254 2024-11-21

KEYNOTE-651

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04135352 2024-11-12

V938-001

35 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasm Metastasis

NCT03833427 2024-11-07

MK-5618-001

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03340766 2024-10-17

HARBOUR

31 enrolled 29 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03996473 2024-10-10

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

8 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03447314 2024-09-23

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

54 enrolled 40 charts

Tumor-Agnostic

Neoplasms

NCT02324582 2024-09-03

MARC

18 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

DermatologicGastrointestinalLymphoidSarcomaThoracic

58 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

GastrointestinalGenitourinaryThoracic

175 enrolled 23 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02808143 2024-06-26

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer